Director, Drug Safety & Pharmacovigilance (Inflammation & Oncology)

About the role

The Director of Drug Safety & Pharmacovigilance provides strategic and hands-on leadership for pharmacovigilance activities supporting a clinical-stage biotech pipeline in inflammatory and oncology diseases. This role is responsible for establishing and executing global safety strategy across early- and mid-stage clinical programs, with particular focus on immune-mediated toxicities, oncology risk management, and complex benefit-risk assessment. The Director partners closely with Clinical Development and Regulatory teams to integrate safety considerations into study design, dose escalation, and development decisions.

Responsibilities

• Develop, implement and lead pharmacovigilance strategy for inflammatory and oncology programs across Phase I-III clinical development.
• Provide expert safety guidance related to immune-mediated adverse events, cytokine-related toxicities, infection risk, malignancy risk, and oncology-specific safety concerns.
• Support dose-escalation and cohort-expansion decisions, including participation in Dose Escalation Committees and Safety Review Committees.
• Maintain ongoing benefit-risk assessments reflecting disease severity, unmet medical need, and evolving clinical data.
• Serve as the primary safety partner to Clinical Development, contributing to protocol design, safety monitoring plans, stopping rules, and risk mitigation strategies.
• Chair or actively participate in Safety Management Teams (SMTs), Joint Safety Forums, and other governance bodies.
• Identify emerging safety signals and ensure appropriate escalation through internal safety governance pathways.
• Oversee intake, medical review, and regulatory submission of Individual Case Safety Reports (ICSRs).
• Ensure high-quality MedDRA coding, oncology-appropriate event characterization, and robust safety narratives.
• Lead safety review meetings and oversee follow-up of serious and immune-mediated adverse events.
• Oversee literature surveillance and safety data collection from investigators, sites, and vendors.
• Lead development and lifecycle management of development-stage Risk Management Plans (RMPs), DSURs, and safety sections of IBs, protocols, ICFs, and clinical study reports.
• Provide safety input to regulatory submissions (IND/CTA), amendments, and responses to health authority questions.
• Support aggregate safety analyses and signal detection activities relevant to oncology and inflammatory disease development.

Requirements

• Bachelor’s degree in a scientific or healthcare-related discipline required, advanced degree (MS, PharmD, PhD, MD, RN) strongly preferred.
• 12+ years of pharmacovigilance or drug safety experience in pharmaceutical or biotechnology settings.
• Direct experience supporting oncology, I/O and/or inflammatory disease clinical programs.
• Experience with early-phase development, dose escalation, and complex safety decision-making.
• Prior involvement in safety governance and regulatory interactions during development.
• Strong knowledge of global PV regulations and guidelines (FDA, EMA, ICH, GCP).
• Experience with safety databases (Argus or equivalent).
• Deep understanding of immune-mediated and oncology-specific safety risks.
• Ability to operate strategically while remaining hands-on in a lean biotech environment.